Human Papillomavirus Recombinant Vaccine from United States
VLP vaccine from HPV L1 protein expression for cervical cancer prevention. This vaccine is a viral biotechnological product for prophylactic use. It is classified under tariff item 3002.49.00 as an 'other' vaccine.
Duty Rate — United States → Canada
0%
Import Tips
• Ensure the vaccine is approved by Health Canada or has a clinical trial authorization
• Provide documentation on the vaccine's composition and manufacturing process
• Declare the product under tariff item 3002.49.00 and be prepared for potential inspection